Skip to main content


  • Correction
  • Open Access

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

  • 1, 2, 3Email author,
  • 1, 2,
  • 1, 2,
  • 1,
  • 3, 4,
  • 1 and
  • 1, 2
Arthritis Research & Therapy201921:69

  • Received: 19 February 2019
  • Accepted: 19 February 2019
  • Published:

The original article was published in Arthritis Research & Therapy 2019 21:54

Correction to: Arthritis Res Ther

Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna’s name. The authors apologise for the error.

Incorrect spelling:

Loreno Dagna

Correct spelling:

Lorenzo Dagna

The original article [1] has been updated.



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy
Vita-Salute San Raffaele University, Milan, Italy
Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA


  1. Cavalli, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther. 2019;21:54 ArticleGoogle Scholar


© The Author(s). 2019